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Substantial data demonstrate that the early-life environment, including in utero, plays a key role
in later life disease. In particular, maternal stress during pregnancy has been linked to adverse
behavioural and emotional outcomes in children. Data from human cohort studies and experi-
mental animal models suggest that modulation of the developing epigenome in the foetus by
maternal stress may contribute to the foetal programming of disease. Here, we summarise
insights gained from recent studies that may advance our understanding of the role of the pla-
centa in mediating the association between maternal mood disorders and offspring outcomes.
First, the placenta provides a record of exposures during pregnancy, as indicated by changes in
the placental trancriptome and epigenome. Second, prenatal maternal mood may alter placental
function to adversely impact foetal and child development. Finally, we discuss the less well
established but interesting possibility that altered placental function, more specifically changes
in placental hormones, may adversely affect maternal mood and later maternal behaviour, which
can also have consequence for offspring well-being.
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Introduction
Pregnancy can be a challenging time in a woman’s life, during which
she may experience many changes in her circumstances. Pregnancy
can also be a time of vulnerability to perinatal mental illnesses,
including depression, stress and postnatal psychosis (1). In the UK,
it is estimated that maternal mood disorders, either prenatally or in
the immediate period after birth, affect approximately one in five
women, and is therefore one of the most common conditions of
pregnancy. These disorders affect women of all ethnicities, national-
ities and social strata (2). In addition to the distress that this causes
women and their families, mental health disorders are one of the
leading causes of death during pregnancy and the year after birth
(1). Of equal concern is an additional consequence for her child’s
well-being, with an increased risk of adverse behavioural and meta-
bolic outcomes following exposure to maternal prenatal stress (3).
Thus, a greater understanding of both the causes and the
consequences of prenatal maternal stress and mood disorders is
imperative.
Foetal programming by maternal stress
Prenatal stress at its broadest level includes major life event
stress, catastrophic disasters, chronic stress, daily hassles, per-
ceived stress or pregnancy-specific anxiety along with related
symptoms of depression or general anxiety during pregnancy (4).
Both animal and human studies indicate that maternal prenatal
stress is associated with an increased risk of adverse emotional,
behavioural and cognitive outcomes in the offspring, a subject
that has been reviewed extensively (5,6). Several studies, including
the large Avon Longitudinal Study of Parents and Children
(ALSPAC) cohort, allow for multiple confounders, including prena-
tal paternal and postnatal maternal mood. The findings from such
studies indicate that the increased risk for adverse outcomes in
the offspring is programmed in utero by the maternal emotional
state, in least in part (7). If the mother is in the top 15% of a
normal population for prenatal symptoms of anxiety or depres-
sion, her child has double the risk of a probable mental disorder,
raised from approximately 6–12% at the age of 13 years (7).
However, it is clear that not all children are affected equally by
exposure to maternal stress, and also the effects of prenatal
stress on child development are inconsistent. Recent data suggest
that this may partly be a result of a gene/environment interplay,
including the interaction between prenatal maternal anxiety and
the child with respect to the genes for brain-derived neurotrophic
factor (BDNF) (8) and catechol-O-methyltransferase (COMT)
(O’Donnell and Glover, unpublished data), during the development
of emotional and cognitive outcomes, respectively.
The role of the placenta in mediating foetal
programming
Placental function is important both for optimal foetal growth and
maternal health (9). The placenta is a transient organ of pregnancy
that transports nutrients and oxygen to the growing foetus and
removes waste products. Additionally, the placenta functions to
mitigate the mother’s immune response to her semi-allogeneic foe-
tus and manufactures large quantities of hormones that flood the
maternal system to induce the adaptations required for a successful
pregnancy (10). An optimally functioning placenta can provide pro-
tection to the foetus against some forms of prenatal adversity. For
example, the placental enzyme 11b-hydroxysteroid dehydrogenase
2 (HSD11B2) regulates foetal exposure to maternal cortisol by con-
verting it to inactive cortisone. Thus, the placenta is able to partially
protect the foetus against elevated maternal cortisol levels. How-
ever, there is evidence that placental function may be affected by
prenatal stress (11–15). Both endogenous and synthetic glucocorti-
coids have been shown to impact a variety of placental functions,
including vascularisation, apoptosis and nutrient transport, in a
range of animal models and human studies (16–20). Moreover,
there is evidence that other maternal factors, such as catecholami-
nes (21), may transfer the effects of maternal stress to the foetus
by altering placental function. Consequently, suboptimal placental
function induced by the maternal state may contribute to altered
and, in our environment, poorer outcomes for children (22). Prena-
tal anxiety is associated with both lower expression and activity of
placental HSD11B2 (14), potentially mitigating the protective role
that this enzyme usually plays, and theoretically exposing the foe-
tus to higher cortisol levels. Foetal glucocorticoid exposure is also
regulated by the placental glucocorticoid (GR; NR3C1) and miner-
alocorticoid (MR; NR3C2) receptors. Placental NR3C1 and NR3C2
expression is higher among depressed compared to nondepressed
new mothers, providing another mechanism for the programming
of adverse offspring outcomes (15). Alterations in the expression of
genes for placental corticotrophin-releasing hormone [pCRH; which
stimulates the production of cortisol via the hypothalamic-pitui-
tary-adrenal (HPA) axis], monoamine oxidase A (MAOA; which
metabolises serotonin into 5-hydroxyindoleacetic acid) and placental
serotonin transporter (SLC6A4; which transports the neurotransmit-
ter serotonin) and P-glycoprotein have also been linked to prenatal
stress (11,23–25). Interestingly, very recent evidence suggests that
the associations between prenatal maternal mood and placental
gene expression may be different in Caucasian and non-Caucasian
populations (Capron and Glover, unpublished data). Thus, alterations
in the expression of a number of genes in the placenta may medi-
ate aspects of foetal programming associated with prenatal stress
(Fig. 1); however, these findings may have ethnic specificities.
Maternal stress and epigenetic changes in the placenta
Although it is clear that there are changes in the expression of
genes in the placenta in relation to prenatal stress exposure, the
mechanisms underpinning these changes are unclear. One possibil-
ity is the epigenetic deregulation of gene expression. Epigenetics
describes the marks or tags that are added or removed from DNA
sequence and the histones that regulate gene expression in a man-
ner heritable through cell division. Such marks may be altered by
exposure to stress during prenatal development, a period when the
epigenome is rapidly changing (26). Animal research demonstrates
that maternal stress can induce epigenetic changes in the placenta.
DNA methylation changes have been reported in the promoter
region of Hsd11B2 (12) and altered chromatin methylation has
been linked to the gene for O-linked-N-acetylglucosamine trans-
ferase (Ogt) (27). Such alterations may be mediated by sex-specific
changes in the placental epigenetic machinery (28). In humans,
maternal anxiety has been linked to greater placental methylation
of HSD11B2, whereas maternal depression (but not anxiety) has
been associated with increased placental methylation of NR3C1
(29). Recent research with mothers in a conflict-ridden region of
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Fig. 1. The role of the placenta in prenatal stress. Prenatal stress can influ-
ence the placental and foetal transcriptomes and epigenomes, which may
contribute to adverse outcomes for children. Dysfunctional placental sig-
nalling may also influence maternal mood during pregnancy and maternal
behaviour in the postnatal period, further contributing to adverse outcomes.
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the Democratic Republic of Congo has reported that higher levels
of war trauma and chronic stress were associated with DNA methy-
lation levels in multiple placental genes involved in HPA axis regu-
lation, including CRH, CRHBP, NR3C1 and FKBP5 (30). Stress-linked
variation in DNA methylation was observed in placental tissue, as
well as maternal and umbilical cord blood. However, similar to Jen-
sen Pena et al. (12), the effects at individual CpG sites differed
between tissues. The majority of CpG sites identified were situated
in transcription factor binding regions, and several were associated
with offspring birth weight (30). Similar effects of maternal war
trauma and chronic stress have been observed with placental BDNF
methylation (31). Considering that many affected CpG sites bind
transcription factors, as well as the associations with mRNA levels
or offspring birth weight, this suggests that stress-linked variation
in placental methylation may have functional consequences for off-
spring outcomes.
Maternal stress and epigenetic changes in offspring
Experimental animal models have demonstrated that early-life
stress can leave a mark on the offspring epigenome, with alter-
ations reported in offspring exposed to prenatal stress (28), mater-
nal separation (32) and low levels of maternal postnatal care (33).
In humans, variation in CpG methylation in umbilical cord blood at
NR3C1 has been associated with prenatal maternal anxiety (34) and
depressive symptoms (29,35). Also in cord blood, CpG methylation
at both NR3C1 and CRH is associated with maternal experiences of
war trauma and chronic stress (30). The NR3C1 and CRH CpG sites
identified in these studies are the same as those linked to pre-
eclampsia in cord blood (36) or prenatal exposure to inter-partner
violence in offspring venous blood (37). In animal models, methyla-
tion at the NR3C1 sites affects NGFI-A binding (38). These may be
sites for which DNA methylation is particularly sensitive to several
stress-linked phenotypes. Prenatal maternal chronic stress and war
trauma is associated with BDNF methylation in cord blood at birth
(31) and prenatal depression has been associated with DNA methy-
lation at the BDNF promoter region in buccal cells at 2 months of
age (39). BDNF plays an essential role in brain development and
has been linked to psychiatric risk (40), thus suggesting that BDNF
DNA methylation may be an important target for future investiga-
tion. Maternal cortisol and self-reported depressive and anxiety
symptoms have also been associated with altered DNA methylation
of the imprinted genes IGF2 and GNASXL (41). However, it is impor-
tant to note that, across both rodent and human studies, there are
tissue specific associations of prenatal stress and DNA methylation.
These differences may reflect the different physiological functions
of each tissue or differences in the epigenetic status of certain tis-
sues at the time of exposure. Nonetheless, it is clear that the
maternal stress can impact both the placental and the foetal epi-
genomes to alter gene expression.
The programming of maternal mood by the placenta
Although considerable data from both animal models and human
studies support changes in the placenta and foetus in response
to maternal stress, which may then contribute to the program-
ming of neurodevelopmental changes in offspring, few studies
have explored a placental origin for maternal mood disorders.
Pituitary prolactin and the placental lactogens are a group of evo-
lutionarily and functionally-related hormones important in preg-
nancy. Human placental lactogen (hPL) is produced by the
placental syncytiotrophoblast and secreted into the maternal cir-
culation, replacing prolactin as the main lactogenic hormone dur-
ing pregnancy (42). Numerous studies highlight a functional role
for these hormones and their shared receptor (prolactin receptor;
PRLR) in the onset of maternal behaviours in rodents and, in the
case of prolactin and PRLR, also maternal neurogenesis (43–53).
In humans, these hormones may contribute to suppression of
anxiety-related behaviours during pregnancy (54). Decreased serum
prolactin levels have been reported in human mothers with post-
natal depression (55,56), whereas increased levels of prolactin
have been associated with low anxiety scores during pregnancy
(57). Impaired hPL production has also been associated with
adverse infant outcomes such as foetal growth restriction (58,59).
Thus, the altered placental expression of the genes for placental
lactogen could contribute to both maternal mood disorders and
adverse outcomes (Fig. 1).
Imprinted genes, foetal programming and maternal mood
disorders
Imprinted genes are expressed from one parental allele through
epigenetic marking in the germline (60). Imprinted genes are
known to regulate foetal growth, placental development, adult
behaviour and metabolism (61). These multifunctional roles and
the flexibility of epigenetic marks have led to the suggestion that
imprinted genes may contribute to the foetal programming of
adverse outcomes (62). Numerous studies have reported the aber-
rant expression of imprinted genes in the placenta in relation to
foetal growth restriction and low birth weight (63). Altered expres-
sion of imprinted genes in the placenta has also been linked to
infant neurobehavioral developmental outcomes (64,65). Recently,
imprinted genes have been highlighted as key regulators of the
endocrine lineages that express placental hormones in rodents
(66). This newly defined function suggests that the aberrant
expression of imprinted genes in the placenta could contribute to
the mispriming of maternal behaviour, at least in rodents, by
modulating exposure of the maternal brain to key placental hor-
mones such as the placental lactogens. If the function of
imprinted genes in regulating the endocrine lineage was conserved
across species, aberrant imprinting could help to explain the co-
occurrence of low birth weight with prenatal mood disorders,
which has been reported in a number of studies (67–73). Epige-
netic changes in cord blood DNA at imprinted loci have been
associated with depressed maternal mood during pregnancy (74)
and with maternal stress (41,75). One study reported changes in
DNA methylation in both cord blood DNA and placental DNA at
an imprinted locus (76). Although it is generally presumed that
such changes occur in response to prenatal adversity with the
focus primarily concerning offspring outcomes, it is possible that
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such changes contribute to altered maternal mood by changing
the endocrine function of the placenta (Fig. 1). Consistent with
this hypothesis, recent data have identified a significant associa-
tion between both symptoms of prenatal depression and clinically
diagnosed depression with placental expression of both an
imprinted gene and placental lactogen, a hormone predicted to be
regulated by this gene (77). Determining the cause and effect
relationships in human studies of pregnancy is challenging. How-
ever, very recent work utilising a novel rodent model suggests
that imprinted genes in the placenta can influence both the
maternal neural transcriptome during pregnancy and maternal
behaviour in the early postnatal period (Creeth et al., in prepara-
tion), comprising data that support a causal relationship.
Summary and outlook
In summary, the placenta plays a key role in supporting a success-
ful healthy pregnancy. The placenta can provide a record of prena-
tal adversity, including maternal stress. Changes in placental
function, potentially driven by epigenetic processes, may impact
neurodevelopmental outcomes for children and both mental and
metabolic health into adulthood. Importantly, placental dysfunction
may also contribute to maternal mood disorders, either during
pregnancy and/or in the immediate postnatal period, by exposing
the mother to abnormal levels of placental hormones. At present,
most women experiencing heightened levels of prenatal depression,
stress and anxiety are undetected and untreated. The potential clin-
ical implications of maternal prenatal mood on foetal and child
neurodevelopment are substantial. The provision of better emotional
care for all pregnant women and enhanced identification and sup-
port for women at particularly high risk of maternal mood disorders
will help not only them, but also their children, and potentially sub-
sequent generations.
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